4-chlorobenzoyl chloride CAS:122-01-0

4-chlorobenzoyl chloride

Chemical Name:4-chlorobenzoyl chloride
CAS.NO:122-01-0
Synonyms:4-chlorobenzoyl chloride
4-Chlorobenzolychloride
para-Chlorobenzoic acid chloride
4-Chlorobenzoylchloride
 
Physical and Chemical Properties:
Density 1.4±0.1 g/cm3
Boiling Point 222.0±0.0 °C at 760 mmHg
Melting Point 12 °C
Molecular Formula C7H4Cl2O
Molecular Weight 175.012
Flash Point 105.0±0.0 °C
Vapour Pressure 0.1±0.4 mmHg at 25°C
Index of Refraction 1.561
 
Specification:
Appearance:Colorless liquid
Assay:≥98.0%
 
Packing:200 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Flumethrin(CAS:69770-45-2) and Dimethomorph(CAS:110488-70-5).



We are professional 3-chlorophenol manufacturer and 4-Chlorobenzoylchloride supplier in China, We offer quality m-monochlorophenol you can fully trust, also we have India factory and producer of m-Cl-phenol,Pls send inquiry of 4-chlorobenzoyl chloride CAS:122-01-0 to info@nbinno.com if you have any interests, thank you!


Related News: The increase in environmental protection pressure has also increased the environmental protection expenditure of pharmaceutical manufacturing companies, which forced some small production capacity to withdraw from the market, increased industry concentration, and brought certain opportunities for API manufacturers.5-Bromo-2-chloropyridine Characteristic APIs are usually more complex in structure, and their synthesis involves a variety of technologies such as chiral synthesis, green synthesis, and catalysis, which requires high research and development capabilities in the production process of API companies.2-Bromotoluene At present, Teva can produce more than 300 generic drugs, and the API department has approximately 650 authorized patents and patent applications worldwide. It is also the generic drug company with the most challenges in patenting ParagraphIV in the world. 2 – [[2 – [(dimetilamino) metil] -1,3-tiazol-4-il] metilsulfanil] etanamina CAS:78441-62-0 This time frame optimizes the opportunity to respond to treatment with an HMA prior to declaring treatment failure, as per NCCN Guidelines. Patients are randomized at a 2:1 ratio into two study arms: IV rigosertib plus Best Supportive Care versus Physician’s Choice plus Best Supportive Care.Some experts said that in the research and development of chemical medicine, the possibility of large medicines is getting smaller and smaller, and with the popularization of precision treatment, small medicines (high-efficiency medicines) are being introduced more and more.